Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HLX301 |
Synonyms | |
Therapy Description |
HLX301 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-L1 (CD274), thereby inhibiting the binding of TIGIT with its ligands CD112 and CD155 and the activation of the PD-L1 receptor, potentially leading to increased antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HLX301 | HLX 301|HLX-301 | PD-L1/PD-1 antibody 119 TIGIT Antibody 19 | HLX301 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-L1 (CD274), thereby inhibiting the binding of TIGIT with its ligands CD112 and CD155 and the activation of the PD-L1 receptor, potentially leading to increased antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05102214 | Phase Ib/II | HLX301 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |